The new data shows human therapeutics. That has the ability the stability of the the stability of the protein drug products. The results of the study show that Recombumin performed many times many times better than the comparators so that it requires an effective multi-purpose excipient with the ability to the total number of agents and reduce thus simplifying the formulation strategy.
Derived from proprietary yeast expression technology Novozymes Biopharma Recombumin the world’s leading animal – free, commercially available recombinant human albumin is of licensed of licensed and developmental human therapeutics. With the stabilization of the benefits of albumin in a GMP compliant and regulatory framework Recombumin ensures high performance and safety of long-term supplier relationships. The agreement with the excipient monograph for recombinant human albumin in the United States Pharmacopoeia published – National Formulary also facilitates regulatory process for customers and sets new standards for recombinant human albumin.B Jung, Cachier A, Baron G, et al decision-making for older patients with severe aortic stenosis: why so many denied operation Am Heart J. 2003; 26:.